IN VIVO ASSESSMENT OF CLINICALLY RELEVANT AUTOANTIBODIES IN IVIG PREPARATIONS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 已在IVIG制剂中检测到自身抗体。有一种理论上的担忧是，自身抗体可能会对接受这些输液的患者造成损害，或者导致静脉注射免疫球蛋白患者的假阳性检测。 这是值得关注的，因为接受IVIG替代治疗的原发免疫缺陷患者随后发展为自身免疫性疾病，可能会用自身抗体水平进行评估。这项研究的目的是确定在没有临床自身免疫性疾病的原发免疫缺陷患者中，IVIG输注后自身抗体效价是否增加。这一数据将有助于解释静脉注射免疫球蛋白患者自身免疫性疾病的血清学测试。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Autoantibodies have been detected in IVIG preparations. There is a theoretical concern that autoantibodies could cause damage to patients receiving these infusions, or cause false positive tests in patients on IVIG. This is of concern because patients with primary immunodeficiency on replacement IVIG therapy who then develop autoimmune disease may be evaluated with autoantibody levels. This study aims to determine whether replacement IVIG infusions in patients with primary immundeficiency who do not have clinical autoimmune disease have increased autoantibody titers post-IVIG infusion. This data will aid in the interpretation of serologic tests for autoimmune disease in patients on IVIG.